KOR was detected in immersion fixed paraffin-embedded sections of human brainstem (medulla) using 15 µg/mL Mouse Anti-Human KOR Monoclonal Antibody (Catalog # MAB38951) overnight at 4 °C. Before incubation with the ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for KOR Antibody (387310) [Unconjugated]
kappa opioid receptor
kappa-type opioid receptor
Opiate receptor, kappa-1
opioid receptor, kappa 1
Kappa Opioid Receptor (KOR) is a 45 kDa 7TM opioid receptor that is primarily expressed in the central nervous system and peripheral visceral pain sensory nerves. Following ligation by dynorphin peptides, KOR signaling induces analgesia, dysphoria, diuresis, and increased feeding desire. KOR also exerts neuroprotective and anti-inflammatory effects. Human KOR shares 94% amino acid sequence identity with mouse and rat KOR.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our KOR Antibody (387310) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.